Case report of 3-year-old girl with bilateral Wilms tumor and TP53 mutation treated with VAD chemotherapy and surgery
3-year-old girl with TP53 mutation and bilateral Wilms tumor died after treatment
This case-based review describes a single 3-year-old girl with bilateral Wilms tumor and a TP53 mutation treated under the Chinese Children …
A single case report describes a 3-year-old girl with bilateral Wilms tumor and a TP53 mutation who died despite aggressive chemotherapy and…
Case review of epithelial-type Wilms tumor in a 23-year-old female with clear surgical margins
A rare kidney tumor in a young adult was removed with clear margins and no spread
This case review describes a 23-year-old female who underwent right radical nephrectomy for a rare epithelial-type Wilms tumor. Histopatholo…
A 23-year-old woman had a rare kidney tumor removed. The surgery showed clear edges and no spread. This case highlights the need for awarene…
Angiogenic ccRCC tumors show higher pancreatic metastasis rate in phase II trial
Pancreatic Metastases Predict Better Sunitinib Response in Kidney Cancer
This phase II RCT of 305 treatment-naive ccRCC patients found that angiogenic tumors had a higher rate of pancreatic metastases (21% vs. 6.9…
Kidney tumors with certain genetic patterns are more likely to spread to the pancreas. Patients with these pancreatic metastases respond bet…
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
BCG plus mitomycin did not improve disease-free survival versus BCG alone in high-risk non-muscle-invasive bladder cancer patients
Adding mitomycin to bladder cancer treatment did not improve survival compared to bacillus calmette-guerin alone in this trial
This randomized Phase 3 trial enrolled 501 BCG-naive patients with high-grade pTa or any grade pT1 non-muscle-invasive bladder cancer. The s…
Doctors tested adding mitomycin to standard bladder cancer therapy. Patients receiving both drugs did not live longer without disease than t…
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
Meta-analysis compares bladder preservation therapy vs cystectomy in elderly muscle-invasive bladder cancer
Bladder Preservation May Be Safe for Older Bladder Cancer Patients
This meta-analysis of 4888 elderly patients with muscle-invasive bladder cancer found no significant difference in 1-, 5-, and 10-year overa…
For older adults with aggressive bladder cancer, keeping the bladder may offer survival rates equal to surgery for the first five years, but…
Systematic review and meta-analysis compares intravesical gemcitabine/docetaxel versus BCG for non-muscle-invasive bladder cancer
Gemcitabine and docetaxel show similar recurrence-free survival to BCG for bladder cancer
This systematic review and meta-analysis evaluated intravesical gemcitabine and docetaxel compared with Bacillus Calmette-Guérin (BCG) in pa…
A meta-analysis of 1634 patients found gemcitabine and docetaxel offered recurrence-free survival rates comparable to BCG therapy for non-mu…
Meta-analysis shows active surveillance and ablative therapy for small renal masses have comparable cancer-specific survival
Active surveillance vs ablation for small kidney tumors: what works?
This systematic review and meta-analysis evaluates active surveillance (AS) versus ablative therapy (AT) for patients with small renal masse…
For small kidney tumors, ablation may boost survival, but cancer-specific death risk is similarly low with either approach.
Prospective study shows active surveillance yields high survival for small renal masses under 2 cm
Small kidney tumors may not need surgery right away
This prospective multi-institutional study evaluated active surveillance in patients aged over 50 years with asymptomatic, unilateral small …
Many small kidney tumors stay harmless for years, meaning patients might avoid surgery and its risks without putting their health in danger.
Case report and literature review on mosaic DICER1 mutations and disease stability in a 6-month-old boy
One Baby, Five Tumors, One Tiny Gene Change
This case report and literature review describes a 6-month-old boy with mosaic DICER1 RNase IIIb hotspot mutation and multiple tumors.
A 6-month-old boy developed five different tumors linked to one small gene change, showing how one mutation can drive multiple childhood can…
Narrative review suggests adjuvant pembrolizumab benefits selected high-risk renal cell carcinoma patients
Old cancer drugs failed, but one new drug saves high-risk kidney patients today
This narrative review evaluates adjuvant therapies for renal cell carcinoma, including cytokine-based immunotherapy, VEGF-targeted agents, a…
Doctors finally have a powerful new tool to stop kidney cancer from coming back after surgery, but it only works for specific patients.
All Urologic Neoplasms Articles
- Case report of 3-year-old girl with bilateral Wilms tumor and TP53 mutation treated with VAD chemotherapy and surgery
- Case review of epithelial-type Wilms tumor in a 23-year-old female with clear surgical margins
- Angiogenic ccRCC tumors show higher pancreatic metastasis rate in phase II trial
- FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
- BCG plus mitomycin did not improve disease-free survival versus BCG alone in high-risk non-muscle-invasive bladder cancer patients
- Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
- Meta-analysis compares bladder preservation therapy vs cystectomy in elderly muscle-invasive bladder cancer
- Systematic review and meta-analysis compares intravesical gemcitabine/docetaxel versus BCG for non-muscle-invasive bladder cancer
- Meta-analysis shows active surveillance and ablative therapy for small renal masses have comparable cancer-specific survival
- Prospective study shows active surveillance yields high survival for small renal masses under 2 cm
- Case report and literature review on mosaic DICER1 mutations and disease stability in a 6-month-old boy
- Narrative review suggests adjuvant pembrolizumab benefits selected high-risk renal cell carcinoma patients
- Open-sourcing data and annotations for renal cell carcinoma yielded 142 annotated CT scans from 101 patients
- Hong Kong consensus statement updates management for locally advanced and metastatic renal cell carcinoma
- Office-based holmium-YAG TULA shows feasibility and safety for recurrent NMIBC in a high-risk cohort
- Real-world analysis finds 34% grade 3-4 adverse events in mRCC patients on immune-based combos
- Comprehensive review compares ICI-based regimens and ICI-TKI combinations against sunitinib in metastatic renal cell carcinoma
- Low ipilimumab trough concentration linked to worse progression-free survival in metastatic clear cell renal cell carcinoma
- Phase 3 RCT Shows Perioperative Enfortumab Vedotin and Pembrolizumab Benefit Muscle-Invasive Bladder Cancer
- Targeted therapy versus non-targeted therapy in renal cell carcinoma patients
- Neoadjuvant nivolumab alone or with ipilimumab in cisplatin-ineligible muscle-invasive bladder cancer
- Durvalumab plus chemotherapy improves event-free and overall survival in muscle-invasive bladder cancer compared to chemotherapy alone
- Predictors of pathological upstaging in clinical stage T1 renal cell carcinoma include male gender, age, and irregular margins
- Simlukafusp alfa plus atezolizumab with or without bevacizumab shows antitumor activity in metastatic renal cell carcinoma
- Late Wilms tumor recurrence observed 32 years after diagnosis in a single case report
- CFP10 immunohistochemistry shows high sensitivity for renal tuberculosis in surgical specimens
- Adjuvant intravesical BCG versus Epirubicin in intermediate-risk non-muscle invasive bladder cancer
- Meta-analysis shows ERAS care improves recovery and reduces complications in laparoscopic nephrectomy for renal cancer
- Phase II trial finds adding gemcitabine to cisplatin-radiotherapy does not improve 2-year disease-free survival in muscle-invasive bladder cancer
- Audit plus peer comparison improved documentation of tumour features and resection completeness in non-muscle-invasive bladder cancer surgery
- Neoadjuvant sacituzumab govitecan plus pembrolizumab shows 39% clinical complete response in MIBC
- Spinal anesthesia associated with lower recurrence than general anesthesia in non-muscle invasive bladder cancer
- CD8 PET imaging shows modest correlation with biopsy CD8 counts in solid tumor patients on immunotherapy
- PI3K-AKT-mTOR pathway activation linked to renal cell carcinoma progression in review